ATP-binding cassette, sub-family B (MDR/TAP), member 1 (ABCB1) polymorphism and clopidogrel concentration in acute coronary syndrome: molecular change can explain the observed therapeutic concentration

References (1)

1. Grove EL, Würtz M, Thomas MR, Kristensen SD. Antiplatelet thera-py in acute coronary syndromes. Expert Opin Pharmacother 2015; 16: 2133-47. 2.Oliphant CS, Trevarrow BJ, Dobesh PP. Clopidogrel response vari-ability: review of the literature and practical considerations. J Pharm Pract 2015; 29: 26-34. 3.Stokanovic D, Nikolic VN, Konstantinovic SS, Zvezdanovic JB, Lilic J, Apostolovic SR, et al. P-Glycoprotein Polymorphism C3435T Is Associated with Dose-Adjusted Clopidogrel and 2-Oxo-Clopidogrel Concentration. Pharmacology 2015; 97: 101-6. 4.Wiwanitkit V. Analysis of binding energy activity of imatinib and Abl tyrosine kinase domain based on simple consideration for confor-mational change: An explanation for variation in imatinib effect in mutated type. Indian J Cancer 2009; 46: 335-6.